Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications - PubMed (original) (raw)
Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications
Bianca Maria Ricerca et al. Mediterr J Hematol Infect Dis. 2009.
Abstract
The clinical approach to thalassemia and hemoglobinopathies, specifically Sickle Cell Disease (SCD), based on transfusions, iron chelation and bone marrow transplantation has ameliorated their prognosis. Nevertheless, infections still may cause serious complications in these patients. The susceptibility to infections in thalassemia and SCD arises both from a large spectrum of immunological abnormalities and from exposure to specific infectious agents. Four fundamental issues will be focused upon as central causes of immune dysfunction: the diseases themselves; iron overload, transfusion therapy and the role of the spleen. Thalassemia and SCD differ in their pathogenesis and clinical course. It will be outlined how these differences affect immune dysfunction, the risk of infections and the types of most frequent infections in each disease. Moreover, since transfusions are a fundamental tool for treating these patients, their safety is paramount in reducing the risks of infections. In recent years, careful surveillance worldwide and improvements in laboratory tests reduced greatly transfusion transmitted infections, but the problem is not completely resolved. Finally, selected topics will be discussed regarding Parvovirus B19 and transfusion transmitted infections as well as the prevention of infectious risk postsplenectomy or in presence of functional asplenia.
Figures
Figure 1.
Risks related to iron overload.
Similar articles
- Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C. Koren A, et al. Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x. Eur J Haematol. 2010. PMID: 19732137 - Thalassemia.
Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Cohen AR, et al. Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review. - Hemoglobinopathies and stroke: strategies for prevention and treatment.
Ali N, Srey R, Pavlakis S. Ali N, et al. Curr Treat Options Cardiovasc Med. 2012 Jun;14(3):227-36. doi: 10.1007/s11936-012-0173-x. Curr Treat Options Cardiovasc Med. 2012. PMID: 22392612 - Erythrocytapheresis in Children and Young Adults with Hemoglobinopathies and Iron Overload in Need of Iron Chelation Therapy.
van Hattem J, Maes P, Esterhuizen TM, Devos A, Ruppert M, van Heerden J. van Hattem J, et al. J Clin Med. 2023 Sep 29;12(19):6287. doi: 10.3390/jcm12196287. J Clin Med. 2023. PMID: 37834930 Free PMC article. - A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients.
Soltani S, Zakeri A, Tabibzadeh A, Zandi M, Ershadi E, Akhavan Rezayat S, Khaseb S, Zakeri AM, Ashtar Nakhaei M, Afzali S, Farahani A. Soltani S, et al. Trop Med Health. 2020 Dec 2;48(1):96. doi: 10.1186/s41182-020-00284-x. Trop Med Health. 2020. PMID: 33292852 Free PMC article. Review.
Cited by
- Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study.
Ehsanipour F, Faranoush P, Foroughi-Gilvaee MR, Sadighnia N, Fallahpour M, Motamedi M, Zandi A, Safaei Z, Zandi A, Faranoush M. Ehsanipour F, et al. Health Sci Rep. 2022 Oct 3;5(6):e871. doi: 10.1002/hsr2.871. eCollection 2022 Nov. Health Sci Rep. 2022. PMID: 36210881 Free PMC article. - The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Weber S, Parmon A, Kurrle N, Schnütgen F, Serve H. Weber S, et al. Front Immunol. 2021 Feb 19;11:627662. doi: 10.3389/fimmu.2020.627662. eCollection 2020. Front Immunol. 2021. PMID: 33679722 Free PMC article. Review. - Immune responses in beta-thalassaemia: heme oxygenase 1 reduces cytokine production and bactericidal activity of human leucocytes.
Nithichanon A, Tussakhon I, Samer W, Kewcharoenwong C, Ato M, Bancroft GJ, Lertmemongkolchai G. Nithichanon A, et al. Sci Rep. 2020 Jun 24;10(1):10297. doi: 10.1038/s41598-020-67346-2. Sci Rep. 2020. PMID: 32581238 Free PMC article. - The ultimate tradeoff: how red cell adaptations to malaria alter the host response during critical illness.
Dobkin J, Wu L, Mangalmurti NS. Dobkin J, et al. Am J Physiol Lung Cell Mol Physiol. 2023 Feb 1;324(2):L169-L178. doi: 10.1152/ajplung.00127.2022. Epub 2023 Jan 3. Am J Physiol Lung Cell Mol Physiol. 2023. PMID: 36594846 Free PMC article. Review. - Transfusion-transmitted infections, its risk factors and impact on quality of life: An epidemiological study among β-thalassemia major children.
Biswas B, Naskar NN, Basu K, Dasgupta A, Basu R, Paul B. Biswas B, et al. Asian J Transfus Sci. 2022 Jan-Jun;16(1):99-105. doi: 10.4103/ajts.AJTS_74_18. Epub 2022 May 26. Asian J Transfus Sci. 2022. PMID: 36199400 Free PMC article.
References
- Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193. - PubMed
- Ladis V, Chouliaras G, Bedousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445–50. - PubMed
- Chern JP, Su S, Lin KH, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer. 2007;48:550–554. - PubMed
- Wanachiwanawin W. Infections in E-beta thalassemia. Pediatr Hematol Oncol. 2000;22(6):581–7. - PubMed
- Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123(2):359–365. - PubMed
LinkOut - more resources
Full Text Sources